| Name | Title | Contact Details |
|---|
Stardust Power Inc. is developing a strategically central, vertically-integrated lithium refinery capable of producing 50,000 tons per annum of battery-grade lithium. Committed to sustainability at each point in the process, the company enjoys a diversified supply of lithium from American brine sources. Stardust is comprised of leading industry, mining and finance experts, supported by a best-in-class advisory board and top technology partners. For more information, visit www.stardust-power.com.
We offer surplus lines products to California agents, primarily homeowners (HO3) and landlord (DF3) policies. Please visit our website for information on how to become appointed.
Founded in 1947 in Milan, Italy RUPES has been an producer of innovative specialty tools for over 70 years. RUPES USA is the North American arm of the Italian based tool manufacturer located in Louisville, Colorado. This location operates as the headquarters for all North American based activities including management, sales, customer support, repair, and manufacturing. In addition to the administrative and business functions of the US headquarters the Colorado location also houses a state of the art training and education facility known as the BigFoot Academy where technicians from a variety of industries can come for industry leading training in a number of disciplines centered on sanding and polishing operations. Visitors to our facility are welcome by appointment only, but we encourage you to contact our US offices via email at info@rupesusa.com to schedule a visit or on-site tour of our new home.
Precision Machining & World-Wide Distribution Center Paragon is a World Class Global Precision Supplier specializing in the Machining and Assembly of Ferrous / Non Ferrous Components for the Automotive and Non Automotive Industries. Our Customers experience Superior Quality, Competitive Cost, and Attentive Service.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.